FlashRNA®, a disruptive and proven alternative to existing RNA delivery technologies
Our technology
An RNA-competent vector for next-generation therapy drugs
FlashRNA® is an innovative RNA delivery solution, and an alternative to the current technologies as it is proprietary and proven from 10 years of expertise.
What is FlashRNA® ?
FlashRNA® is a particle carrying biological RNAs, manufactured with a biological process.
FlashRNA® combines the very efficient cell transfer function of a lentivirus with the RNA packaging system of a bacteriophage. This combination offers unparalleled performance for delivering multiple RNAs to cells, in vitro and in vivo.
All FlashRNA® components are synthesized in human producer cells. So, FlashRNA® encapsulates biological RNAs of human origin and not synthetic, in vitro-transcribed RNA, like LNPs. Moreover, FlashRNA® is a complex, multi-layered structure allowing protection of the packaged RNAs. Thus, as a bioengineered virus-like particle (VLP), FlashRNA® has a lower intrinsic immunogenicity and highly efficient entry into a broad range of cell types, compared to LNPs.
Discover the groundbreaking potential of FlashRNA®: a revolutionary vector that is changing the game of RNA delivery
Delivery Capability
- Multiple RNAs carried in a single batch
- High payload capacity: up to 10kb long
- Delivery of distincts RNAs types such as mRNAs, guide RNAs, coding & non-coding RNAs…
Efficacy
- High transduction efficiency in any target cell in vitro & in vivo
- Transient & high expression of your mRNA sequence(s)
- Fast protein(s) expression within 4H post-transduction
Safety
- No risk of insertionnal mutagenesis thanks to the total absence of integrase in the particle
- No adverse immune response thanks to the biological origin of RNAs and the structure of the particles
- RNA protected from degradation by the multi-layers structure of the FlashRNA® particle
- No toxicity, preservation of the viability and the original cell phenotype
Ten years of combined data from many joint projects and in-house tests
Two complementary ways to use and access FlashRNA® technology
Try it as R&D grade batches production
FlashRNA® particles can be provided in different formats
- Premade samples, carrying a fluorescent reporter, Luciferase, Cre recombinase or Cas9 nuclease
- Custom particles, carrying your gene(s) of interest. Contact us to tell us about your specific need.
Use it through a license agreement
- From R&D to Market: Licensing agreements tailored to support every stage, from discovery to clinical and commercial use.
- Tech Transfer: Structured transfer to qualified CDMOs to ensure robust, GMP-compliant production.
- Versatility of Applications: Gene therapy, cell therapy, vaccines, immuno-oncology, and regenerative medicine.
- Dedicated Partnership: Scientific support to maximize impact and accelerate your innovation roadmap.
Redefine the possibilities for cell & gene therapy, cell reprogramming, vaccine development, and beyond
FlashRNA® is an RNA delivery system developed for all kinds of RNA therapy applications.
Enter the next generation of regenerative medicine / cell and gene therapy tools with FlashRNA®, our innovative technology for precise and efficient delivery of RNA molecules, designed for limitless possibilities.
Thanks to a successful scaling-up of its production process, FlashRNA® is ready to be used as a Drug Product in a phase ½ clinical study in 2025.
Our experience in GMP-compliant production and regulatory validation ensure a smooth path to clinical trials. From concept to GMP production, we provide comprehensive assistance throughout your RNA therapeutic development journey.
FlashRNA® technology is protected by 3 patents owned by RNAlead
An RNA-competent vector for next-generation therapy drugs
FlashRNA
-Foundation Platform-
Retroviral particle comprising at least two encapsidated non-viral RNAs
Genome Editing
-Specialized Platform-
Particle for the encapsidation of a genome engineering system
Immunotherapy
-Specialized Platform-
Viral particle for RNA transfer, especially into cells involved in immune response
FAQ
What is the nature of RNA packaged in FlashRNA® particles?
RNA incorporated within FlashRNA® particles is transcribed endogenously in producer cells during particle assembly, thereby constituting biological RNA rather than synthetic, in vitro–transcribed RNA. As a consequence, these RNAs possess the full repertoire of natural post-transcriptional modifications introduced by human cellular machinery, reflecting authentic modification patterns found in physiologically expressed RNA species.
What are the differences between FlashRNA® and LNPs?
LNPs are synthetic, whereas FlashRNA® is biologically derived. All FlashRNA® components are synthesized in human producer cells. So, FlashRNA® encapsulates biological RNAs of human origin and not synthetic, in vitro-transcribed RNA, like LNPs. Moreover, FlashRNA® is a complex, multi-layered structure allowing protection of the packaged RNAs, thanks to a protein capsid surrounded by a biological lipid membrane. Thus, as a bioengineered virus-like particle (VLP), FlashRNA® has a lower intrinsic immunogenicity and highly efficient entry into a broad range of cell types, compared to LNPs.
What types of RNA can FlashRNA® deliver?
FlashRNA® can deliver various RNA types, including mRNAs, guide RNAs, coding and non-coding RNAs. For example, for gene editing, Cas9 mRNA and single guide RNAs can be packaged within the same particle.
What is the maximum RNA payload capacity of FlashRNA®?
FlashRNA® technology supports a high payload capacity, enabling the delivery of both small and large RNAs. Specifically, it can deliver multiple RNA molecules, including large RNAs up to 10 kilobases (kb) in length. This makes FlashRNA® suitable for complex applications such as cell reprogramming, gene editing, and immunotherapy, where the simultaneous delivery of several and/or large RNA molecules is required.
Is there generation of DNA after RNA transfer by FlashRNA®?
No, the delivered RNAs are directly used by the target cell. There is no possibility of reverse transcription nor integration, as the LTRs and integrase have been deleted.
Is FlashRNA® already used in therapy?
Yes, FlashRNA® has been produced as a Drug Product, to be used for a First-in-Human phase 1/2 clinical trial in 2025 (LymphARN trial, to treat secondary lymphedema).
Contact us
Do you have a project in mind? We’d love to hear from you!
